Literature DB >> 11507200

Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2.

S Sato1, S K Wong, D W Lazinski.   

Abstract

A host-mediated RNA-editing event allows hepatitis delta virus (HDV) to express two essential proteins, the small delta antigen (HDAg-S) and the large delta antigen (HDAg-L), from a single open reading frame. One or several members of the ADAR (adenosine deaminases that act on RNA) family are thought to convert the adenosine to an inosine (I) within the HDAg-S amber codon in antigenomic RNA. As a consequence of replication, the UIG codon is converted to a UGG (tryptophan [W]) codon in the resulting HDAg-L message. Here, we used a novel reporter system to monitor the editing of the HDV amber/W site in the absence of replication. In cultured cells, we observed that both human ADAR1 (hADAR1) and hADAR2 were capable of editing the amber/W site with comparable efficiencies. We also defined the minimal HDV substrate required for hADAR1- and hADAR2-mediated editing. Only 24 nucleotides from the amber/W site were sufficient to enable efficient editing by hADAR1. Hence, the HDV amber/W site represents the smallest ADAR substrate yet identified. In contrast, the minimal substrate competent for hADAR2-mediated editing contained 66 nucleotides.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507200      PMCID: PMC115100          DOI: 10.1128/jvi.75.18.8547-8555.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Editing of messenger RNA precursors and of tRNAs by adenosine to inosine conversion.

Authors:  W Keller; J Wolf; A Gerber
Journal:  FEBS Lett       Date:  1999-06-04       Impact factor: 4.124

2.  Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen.

Authors:  M Y Kuo; M Chao; J Taylor
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

3.  Ca2+ permeability of KA-AMPA--gated glutamate receptor channels depends on subunit composition.

Authors:  M Hollmann; M Hartley; S Heinemann
Journal:  Science       Date:  1991-05-10       Impact factor: 47.728

4.  A specific base transition occurs on replicating hepatitis delta virus RNA.

Authors:  G X Luo; M Chao; S Y Hsieh; C Sureau; K Nishikura; J Taylor
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

5.  Molecular cloning of hepatitis delta virus RNA from an infected woodchuck liver: sequence, structure, and applications.

Authors:  M Y Kuo; J Goldberg; L Coates; W Mason; J Gerin; J Taylor
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

6.  A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta.

Authors:  A J Weiner; Q L Choo; K S Wang; S Govindarajan; A G Redeker; J L Gerin; M Houghton
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

7.  Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells.

Authors:  J Berger; J Hauber; R Hauber; R Geiger; B R Cullen
Journal:  Gene       Date:  1988-06-15       Impact factor: 3.688

8.  Hepatitis delta virus genome replication: a polyadenylated mRNA for delta antigen.

Authors:  S Y Hsieh; M Chao; L Coates; J Taylor
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Substrate recognition by ADAR1 and ADAR2.

Authors:  S K Wong; S Sato; D W Lazinski
Journal:  RNA       Date:  2001-06       Impact factor: 4.942

10.  Structure, sequence and expression of the hepatitis delta (delta) viral genome.

Authors:  K S Wang; Q L Choo; A J Weiner; J H Ou; R C Najarian; R M Thayer; G T Mullenbach; K J Denniston; J L Gerin; M Houghton
Journal:  Nature       Date:  1986 Oct 9-15       Impact factor: 49.962

View more
  36 in total

1.  Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2.

Authors:  Geetha C Jayan; John L Casey
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 2.  RNA editing by adenosine deaminases that act on RNA.

Authors:  Brenda L Bass
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

3.  Elevated activity of the large form of ADAR1 in vivo: very efficient RNA editing occurs in the cytoplasm.

Authors:  Swee Kee Wong; Shuji Sato; David W Lazinski
Journal:  RNA       Date:  2003-05       Impact factor: 4.942

4.  By inhibiting replication, the large hepatitis delta antigen can indirectly regulate amber/W editing and its own expression.

Authors:  Shuji Sato; Cromwell Cornillez-Ty; David W Lazinski
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 5.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

6.  Roles of carboxyl-terminal and farnesylated residues in the functions of the large hepatitis delta antigen.

Authors:  Brendan O'Malley; David W Lazinski
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Crystallization and X-ray diffraction analysis of the Trp/amber editing site of hepatitis delta virus (+)RNA: a case of rational design.

Authors:  Celeste MacElrevey; Joseph E Wedekind
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-11-12

8.  Effects of conserved RNA secondary structures on hepatitis delta virus genotype I RNA editing, replication, and virus production.

Authors:  Geetha C Jayan; John L Casey
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Evidence for auto-inhibition by the N terminus of hADAR2 and activation by dsRNA binding.

Authors:  Mark R Macbeth; Arunth T Lingam; Brenda L Bass
Journal:  RNA       Date:  2004-10       Impact factor: 4.942

10.  Evolution and diversity of the human hepatitis d virus genome.

Authors:  Chi-Ruei Huang; Szecheng J Lo
Journal:  Adv Bioinformatics       Date:  2010-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.